ClinicalTrials.gg
TerminatedNCT01035346Updated Aug 21, 2012Results posted

Study Evaluating The Efficacy Of A Novel Ibuprofen Formulation On Fever In Patients With An Uncomplicated Acute Infection

A Phase 3 interventional study of Ibuprofen and Placebo in Infection, sponsored by Pfizer. Terminated at 5 sites in United States. Open to participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2012-08-21.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
12 Years to 65 Years
Sex
All
01

Study summary

This single-dose trial will evaluate the efficacy of a novel ibuprofen formulation compared to placebo in patients with a fever due to an uncomplicated acute infection.

02

Conditions studied

  • Infection

Browse trials for

Keywords

  • Fever
  • antipyretic
  • uncomplicated acute viral infection
  • uncomplicated acute bacterial infections
03

In context

Infections

2,096 studies on the registry are indexed under Infections; 362 are open to participants now.

This study's enrollment of 16 is below the median of 113 across 1,305 interventional studies indexed under Infections.

Browse Infections studies →

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects diagnosed with a fever secondary to an uncomplicated acute viral or bacterial infection.
  • Oral temperature measurement from 100 to 104 degrees Fahrenheit.
  • Onset of fever 3 days or less.
  • Otherwise good health.

Exclusion criteria

Exclusion Criteria:

  • Fever secondary to a chronic underlying medical condition or serious infection.
  • Currently taking antibiotics or antivirals.
  • Currently taking any medication which may interfere with the assessment of fever.
  • Pregnancy or breast-feeding.
  • Any serious medical or psychiatric disorder.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    A

    Drug: Ibuprofen

  • Placebo comparator
    B

    Drug: Placebo

Interventions

  • Single dose of a novel ibuprofen formulation (equal to 400mg ibuprofen)

  • DrugPlacebo

    Single dose of a placebo

06

What researchers measure

Primary outcomes

  1. Time-weighted Sum of The Temperature Differences From Baseline Through Hour 6 (STEMPD 0-6)

    STEMPD 0-6 was defined as time-weighted sum of temperature differences over 6 hours, weighted by the time elapsed between each 2 consecutive time points. Temperature difference was defined as baseline temperature minus post-baseline temperature at each time point, where positive value indicated improvement in body temperature.

    Time frame: 0 to 6 hours

Secondary outcomes

  1. Time-weighted Sum of The Temperature Differences From Baseline Through Hour 4 and Hour 8 (STEMPD 0-4 and STEMPD 0-8)

    STEMPD 0-4 and STEMPD 0-8 were defined as the time-weighted sum of temperature differences over 4 hours and 8 hours, weighted by the time elapsed between each 2 consecutive time points. Temperature difference was defined as baseline temperature minus post-baseline temperature at each time point, where positive value indicated improvement in body temperature.

    Time frame: 0 to 4, 0 to 8 hours

  2. Change From Baseline in Temperature at Hours 0.25, 0.5, 1, 2, 4, 6 and 8

    Change from baseline in temperature was calculated as baseline temperature minus post-baseline temperature at each time point, where positive value indicated improvement in body temperature.

    Time frame: Baseline, 0.25, 0.5, 1, 2, 4, 6, 8 hours

  3. Time to Treatment Failure

    Median time of dropping out of the participants from the study due to lack of efficacy or use of rescue medication, whichever comes first.

    Time frame: 0 to 8 hours

  4. Cumulative Percentage of Participants With Treatment Failure

    Percentage of participants who withdrew from the study due to lack of efficacy or received rescue medication.

    Time frame: 0.25, 0.5, 1, 2, 4, 6, 8 hours

  5. Global Assessment of Study Medication as an Antipyretic

    Global assessment of study medication was performed at the 8-hours time point or immediately before taking rescue medication (if necessary). It was scored on a 5-point categorical scale where 0=poor, 1=fair, 2=good, 3=very good, and 4=excellent.

    Time frame: 8 hours

  6. Rating of Study Medication Relative to Usual Medication

    Rating of study medication was performed at the 8-hours time point or immediately before taking rescue medication (if necessary). It was scored on a 5-point categorical scale where 0=poor, 1=fair, 2=good, 3=very good, and 4=excellent.

    Time frame: 8 hours

07

Results

Posted Aug 21, 2012
Limitations and caveats
Definitive conclusion could not be made due to early termination of study, due to low enrollment rate, and small number of enrolled participants.

Participant flow

Participant flow — Overall Study
MilestonePlaceboIbuprofen Sodium
Started79
Completed79
Not completed00

Outcome measures

PrimaryTime-weighted Sum of The Temperature Differences From Baseline Through Hour 6 (STEMPD 0-6)

STEMPD 0-6 was defined as time-weighted sum of temperature differences over 6 hours, weighted by the time elapsed between each 2 consecutive time points. Temperature difference was defined as baseline temperature minus post-baseline temperature at each time point, where positive value indicated improvement in body temperature.

Time frame:
0 to 6 hours
Reported as:
Mean · Degrees Fahrenheit
Time-weighted Sum of The Temperature Differences From Baseline Through Hour 6 (STEMPD 0-6)
Degrees FahrenheitPlaceboIbuprofen Sodium
Time-weighted Sum of The Temperature Differences From Baseline Through Hour 6 (STEMPD 0-6)3.0 ± 6.310.8 ± 4.9
Statistical analysis
  • Placebo vs Ibuprofen Sodium · ANOVA · p = 0.228 (p-value was calculated using ANOVA model with treatment and baseline temperature terms. Statistical testing was done at 5% significance level (2-sided).) · Least-squares (ls) mean difference: 8.33 · 95% CI -7.94 to 24.60
SecondaryTime-weighted Sum of The Temperature Differences From Baseline Through Hour 4 and Hour 8 (STEMPD 0-4 and STEMPD 0-8)

STEMPD 0-4 and STEMPD 0-8 were defined as the time-weighted sum of temperature differences over 4 hours and 8 hours, weighted by the time elapsed between each 2 consecutive time points. Temperature difference was defined as baseline temperature minus post-baseline temperature at each time point, where positive value indicated improvement in body temperature.

Time frame:
0 to 4, 0 to 8 hours
Reported as:
Mean · Degrees Fahrenheit
Time-weighted Sum of The Temperature Differences From Baseline Through Hour 4 and Hour 8 (STEMPD 0-4 and STEMPD 0-8)
Degrees FahrenheitPlaceboIbuprofen Sodium
STEMPD 0-41.7 ± 3.96.7 ± 2.9
STEMPD 0-85.7 ± 9.413.4 ± 7.3
Statistical analysis
  • Placebo vs Ibuprofen Sodium · ANOVA · p = 0.171 (p-value was calculated using ANOVA model with treatment and baseline temperature terms. Statistical testing was done at 5% significance level (2-sided).) · Ls mean difference: 5.99 · 95% CI -3.99 to 15.97
  • Placebo vs Ibuprofen Sodium · ANOVA · p = 0.354 (p-value was calculated using ANOVA model with treatment and baseline temperature terms. Statistical testing was done at 5% significance level (2-sided).) · Ls mean difference: 8.96 · 95% CI -14.78 to 32.69
SecondaryChange From Baseline in Temperature at Hours 0.25, 0.5, 1, 2, 4, 6 and 8

Change from baseline in temperature was calculated as baseline temperature minus post-baseline temperature at each time point, where positive value indicated improvement in body temperature.

Time frame:
Baseline, 0.25, 0.5, 1, 2, 4, 6, 8 hours
Reported as:
Mean · Degrees Fahrenheit
Change From Baseline in Temperature at Hours 0.25, 0.5, 1, 2, 4, 6 and 8
Degrees FahrenheitPlaceboIbuprofen Sodium
0.25 hours0.4 ± 0.40.4 ± 0.3
0.5 hours0.5 ± 0.40.7 ± 0.4
1 hour0.3 ± 0.71.2 ± 0.7
2 hours0.8 ± 1.01.9 ± 0.9
4 hours0.3 ± 1.52.0 ± 0.9
6 hours0.7 ± 1.52.1 ± 1.3
8 hours1.3 ± 1.71.3 ± 1.9
Statistical analysis
  • Placebo vs Ibuprofen Sodium · ANOVA · p = 0.576 (p-value was calculated using ANOVA model with treatment and baseline temperature terms. Statistical testing was done at 5% significance level (2-sided).) · Ls mean difference: -0.15 · 95% CI -0.84 to 0.54
  • Placebo vs Ibuprofen Sodium · ANOVA · p = 0.502 (p-value was calculated using ANOVA model with treatment and baseline temperature terms. Statistical testing was done at 5% significance level (2-sided).) · Ls mean difference: 0.18 · 95% CI -0.50 to 0.87
  • Placebo vs Ibuprofen Sodium · ANOVA · p = 0.116 (p-value was calculated using ANOVA model with treatment and baseline temperature terms. Statistical testing was done at 5% significance level (2-sided).) · Ls mean difference: 1.31 · 95% CI -0.51 to 3.12
  • Placebo vs Ibuprofen Sodium · ANOVA · p = 0.161 (p-value was calculated using ANOVA model with treatment and baseline temperature terms. Statistical testing was done at 5% significance level (2-sided).) · Ls mean difference: 1.58 · 95% CI -0.98 to 4.14
  • Placebo vs Ibuprofen Sodium · ANOVA · p = 0.215 (p-value was calculated using ANOVA model with treatment and baseline temperature terms. Statistical testing was done at 5% significance level (2-sided).) · Ls mean difference: 1.87 · 95% CI -1.66 to 5.41
  • Placebo vs Ibuprofen Sodium · ANOVA · p = 0.388 (p-value was calculated using ANOVA model with treatment and baseline temperature terms. Statistical testing was done at 5% significance level (2-sided).) · Ls mean difference: 1.17 · 95% CI -2.18 to 4.52
  • Placebo vs Ibuprofen Sodium · ANOVA · p = 0.849 (p-value was calculated using ANOVA model with treatment and baseline temperature terms. Statistical testing was done at 5% significance level (2-sided).) · Ls mean difference: 0.31 · 95% CI -3.98 to 4.61
SecondaryTime to Treatment Failure

Median time of dropping out of the participants from the study due to lack of efficacy or use of rescue medication, whichever comes first.

Time frame:
0 to 8 hours
Reported as:
Median · hours
Time to Treatment Failure
hoursPlaceboIbuprofen Sodium
Time to Treatment FailureNA (NA to NA)NA (NA to NA)
SecondaryCumulative Percentage of Participants With Treatment Failure

Percentage of participants who withdrew from the study due to lack of efficacy or received rescue medication.

Time frame:
0.25, 0.5, 1, 2, 4, 6, 8 hours
Reported as:
Number · percentage of participants
Cumulative Percentage of Participants With Treatment Failure
percentage of participantsPlaceboIbuprofen Sodium
0.25 hours0.00.0
0.5 hours0.00.0
1 hour0.00.0
2 hours0.00.0
4 hours0.00.0
6 hours0.00.0
8 hours0.011.1
Statistical analysis
  • Placebo vs Ibuprofen Sodium · Cochran-Mantel-Haenszel · p = 0.378 (p-value was calculated using CMH general association test using table scores. Statistical testing was done at 5% significance level (2-sided).) · Difference in proportion: 11.11 · 95% CI -10.67 to 32.89
SecondaryGlobal Assessment of Study Medication as an Antipyretic

Global assessment of study medication was performed at the 8-hours time point or immediately before taking rescue medication (if necessary). It was scored on a 5-point categorical scale where 0=poor, 1=fair, 2=good, 3=very good, and 4=excellent.

Time frame:
8 hours
Reported as:
Mean · units on a scale
Global Assessment of Study Medication as an Antipyretic
units on a scalePlaceboIbuprofen Sodium
Global Assessment of Study Medication as an Antipyretic1.8 ± 1.52.5 ± 1.1
Statistical analysis
  • Placebo vs Ibuprofen Sodium · Cochran-Mantel-Haenszel · p = 0.324 (p-value was calculated using CMH test with modified ridit scores. Statistical testing was done at 5% significance level (2-sided).) · Mean difference (final values): 0.48 · 95% CI -0.30 to 1.27
SecondaryRating of Study Medication Relative to Usual Medication

Rating of study medication was performed at the 8-hours time point or immediately before taking rescue medication (if necessary). It was scored on a 5-point categorical scale where 0=poor, 1=fair, 2=good, 3=very good, and 4=excellent.

Time frame:
8 hours
Reported as:
Mean · units on a scale
Rating of Study Medication Relative to Usual Medication
units on a scalePlaceboIbuprofen Sodium
Rating of Study Medication Relative to Usual Medication1.5 ± 1.42.4 ± 1.1
Statistical analysis
  • Placebo vs Ibuprofen Sodium · Cochran-Mantel-Haenszel · p = 0.210 (p-value was calculated using CMH test with modified ridit scores. Statistical testing was done at 5% significance level (2-sided).) · Mean difference (final values): 0.53 · 95% CI -0.12 to 1.18

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/7 (0%)1/7 (14.3%)
Ibuprofen Sodium—0/9 (0%)3/9 (33.3%)
Most frequent other events
Most frequent other events
EventPlaceboIbuprofen Sodium
PainGeneral disorders1/70/9
Oropharyngeal painRespiratory, thoracic and mediastinal disorders1/70/9
Cold sweatGeneral disorders0/71/9
FatigueGeneral disorders0/71/9
MalaiseGeneral disorders0/71/9
PruritusSkin and subcutaneous tissue disorders0/71/9

Baseline characteristics

Age Continuous
Age Continuous(years)PlaceboIbuprofen SodiumTotal
Mean31.4 ± 15.337.3 ± 17.934.8 ± 16.5
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboIbuprofen SodiumTotal
Female246
Male5510
Body Temperature
Body Temperature(Degrees Fahrenheit)PlaceboIbuprofen SodiumTotal
Mean100.99 ± 0.83100.58 ± 0.66100.76 ± 0.74
08

Study locations

5 sites
  • Pfizer Investigational Site
    Cypress, California 90630, United States
  • Pfizer Investigational Site
    Westlake Village, California 91361, United States
  • Pfizer Investigational Site
    Omaha, Nebraska 68144, United States
  • Pfizer Investigational Site
    Pittsburgh, Pennsylvania 15241, United States
  • Pfizer Investigational Site
    Salt Lake City, Utah 84124, United States
09

References and documents

Publications

  • Jayawardena S, Leyva R, Kellstein D. Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo. Postgrad Med. 2015 Jan;127(1):33-7. doi: 10.1080/00325481.2015.993268. Epub 2014 Dec 15. PubMed 25526232 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2010, a primary completion of May 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2012, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2009
First posted
Dec 18, 2009
Start
Jan 2010
Primary completionActual
May 2011
CompletionActual
May 2011
Results first posted
Aug 21, 2012
Last update
Aug 21, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01035346
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Dec 18, 2009
Start date
Jan 2010
Primary completion
May 2011
Completion
May 2011
Results posted
Aug 21, 2012
Last update
Aug 21, 2012

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibuprofen

Start the discussion